胰高血糖素样肽1受体激动剂使用与青光眼发病率:系统综述与Meta分析
该系统综述与Meta分析纳入5项回顾性研究、共156042名基于常规收集电子数据的参与者,比较2型糖尿病患者使用GLP-1受体激动剂(GLP-1 RA)与非使用者的青光眼发病率。汇总分析显示两组青光眼发病率无显著统计学差异(HR 0.779 [95%CI 0.585-11.036];P=.086;I²=86%)。剔除Shao等研究后,GLP-1 RA使用者青光眼发病率显著降低(HR 0.71 [95%CI 0.60-0.85],I²=29%)。
要点
- 汇总5项回顾性研究、156042名参与者,GLP-1 RA与对照组青光眼发病率无显著统计学差异(HR 0.779;P=.086;I²=86%)。
- 剔除Shao等研究后,GLP-1 RA组青光眼发病率显著降低(HR 0.71 [95%CI 0.60-0.85],I²=29%)。
- 作者结论认为回顾性研究中GLP-1 RA使用与青光眼发生减少相关,但总体解读应谨慎。
核心结论
- 该系统Meta分析发现,在回顾性研究中GLP-1 RA使用与青光眼发生减少相关。
- 作者认为需要未来设计良好的长期研究聚焦GLP-1 RA与SGLT-2抑制剂以验证这些发现并评估其对青光眼进展和视力丧失的影响。
- 作者指出总体解读应谨慎。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Web of Science和Cochrane数据库自1991年7月至2024年5月比较GLP-1 RA使用者与非使用者青光眼发病率的研究。
- 共识别194项研究,其中5项回顾性研究符合纳入标准,基于常规收集电子数据共纳入156042名参与者。
- 采用随机效应模型计算GLP-1 RA组与对照个体的汇总风险比。
主要发现
- Meta分析显示GLP-1 RA使用者与对照个体相比青光眼发病率无显著统计学差异(HR 0.779 [95%CI 0.585-11.036];P=.086;I²=86%)。
- 留一法敏感性分析中,纳入Shao等研究产生相反效应,提示SGLT-2抑制剂在预防青光眼方面可能不劣于或可能优于GLP-1 RA。
- 剔除该研究后,GLP-1 RA使用者与对照个体相比青光眼发病率显著降低,异质性降低(HR 0.71 [95%CI 0.60-0.85],I²=29%)。
- 研究存在中度偏倚担忧,原因为混杂因素和干预分类。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入的5项研究均为回顾性研究。
- 研究存在中度偏倚担忧,原因为混杂因素和干预分类。
- 汇总分析异质性 I²=86%。
- 作者指出未来需要设计良好的长期研究聚焦GLP-1 RA与SGLT-2抑制剂以验证这些发现。
- 作者指出总体解读应谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients with diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) may protect against microvascular alterations and oxidative stress, both of which have been implicated in glaucoma. Multiple studies suggest a possible relation between GLP-1 RA use and the development of glaucoma. This study is a systematic review of the published literature regarding the incidence of glaucoma development in patients with type 2 diabetes treated with GLP-1 RAs compared with a control group. DESIGN: A systematic review and meta-analysis. METHODS: We searched PubMed, Embase, Web of Science, and Cochrane databases from July 1991 to May 2024 for studies comparing the incidence of glaucoma development in GLP-1 RA users versus nonusers. We calculated the pooled hazard ratio for the GLP-1 RA group and control individuals using a random-effects model. RESULTS: One hundred ninety-four studies were identified, of which 5 retrospective studies met the inclusion criteria, with a total of 156,042 participants based on routinely collected electronic data. The meta-analysis revealed no significant statistical difference in glaucoma incidence among GLP-1 RA users compared with control individuals (hazard ratio 0.779 [95% CI 0.585-11.036]; P = .086; I2 = 86%). During the leave-one-out sensitivity analysis, the inclusion of the study by Shao and associates yielded opposite effects, suggesting that SGLT-2 inhibitors might be as effective as, or potentially more effective than, GLP-1 RAs in preventing glaucoma. When this study was excluded from the analysis, the results demonstrated a significant reduction in the incidence of glaucoma among GLP-1 RA users compared with control individuals, with reduced heterogeneity (hazard ratio 0.71 [95% CI 0.60-0.85], I² = 29%). Studies had moderate bias concerns because of confounding factors and intervention classification. CONCLUSION: This systematic meta-analysis found that GLP-1 RA use is associated with reduced glaucoma development in retrospective studies. Future well-designed, long-term studies focusing on GLP-1 RAs and SGLT-2 inhibitors are needed to validate these findings and evaluate their effects on glaucoma progression and vision loss. The overall interpretation should be cautious.
引用
- Amaral DC, Guedes J, Cruz MRB, et al. GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2024. PMID: 39732312. doi:10.1016/j.ajo.2024.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。